Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Taking Control – Risks vs. Benefits July 14, 2020 Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer... August 24, 2020 Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 Immunotherapy Effective in Alveolar Soft Part Sarcoma January 9, 2019 Load more HOT NEWS ¿Es seguro el CBD para las personas con cáncer? FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story For People with Cancer, Are Steroids the Best Treatment for Breathing...
